E-Nitiate Biopharmaceuticals Hangzhou Co. Ltd.

This is a randomized, double-blind, multicenter, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of QY101 ointment in adult patients with plaque psoriasis. The primary objective is to evaluate the efficacy of QY101 ointment in adult patients with plaque psoriasis (2-20% BSA). The secondary objective is to evaluate the safety of QY101 ointment in adult patients with plaque psoriasis (2-20% BSA).

This study is a randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of single and multiple topical administration of QY211 gel in healthy Chinese subjects and patients with mild to moderate atopic dermatitis. The main purpose is to evaluate the safety and tolerability of QY211 gel in healthy Chinese subjects and patients with mild to moderate atopic dermatitis. The study is divided into Part 1 and Part 2: Part 1 is a single-center, randomized, double-blind, placebo-controlled single and multiple administration, dose escalation study conducted in healthy adult subjects in China. It is divided into three groups. Part 2 is a multicenter, randomized, double-blind, placebo-controlled multiple administration, dose escalation study conducted in patients with mild to moderate atopic dermatitis in China. It is divided into four groups.